For more on Cybin, see our interview with CEO Doug Drysdale
https://www.instagram.com/reel/CoVSirXLu8K/?utm_source=ig_web_copy_link&igshid=MzRlODBiNWFlZA==
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
– Cohort 5 completed with no safety or tolerability issues, Final cohort 6 is recruiting with dosing expected to commence shortly
– Phase 2 efficacy data for CYB003 in major depressive disorder expected in Q3/Q4 2023
– U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2a data for pivotal studies expected following topline efficacy data readout
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that its Phase 2 trial evaluating CYB003, an investigational proprietary deuterated analog of psilocybin for the potential treatment of major depressive disorder (“MDD”), has completed dosing in Cohort 5 with no serious adverse events or other adverse events that may preclude continued dosing. The completed Cohorts 4 and 5 evaluated two 12mg doses of CYB003, and recruitment is underway to commence dosing for Cohort 6, the final cohort in the Phase 2 portion of the study.
“The completion of CYB003 dosing in Cohort 5 represents a significant milestone in the progression of our Phase 2 study, taking us one step closer towards establishing a therapeutically efficacious dose and advancing CYB003 towards pivotal studies with the goal of bringing CYB003 as a differentiated and rapid-acting therapeutic option for people with major depressive disorder,” said Doug Drysdale, Chief Executive Officer of Cybin. “We are proud of the speed with which we have advanced our clinical-stage programs and remain on track to deliver topline efficacy data from this Phase 2 study later this year and submit data to the FDA in preparation for a potential pivotal study of CYB003.”
To date, CYB003 has demonstrated a favorable safety and tolerability profile with no serious adverse events reported at the doses evaluated (1mg, 3mg, 8mg, 10mg, and 12 mg). Interim findings from the Phase 1/2a study have also demonstrated positive observations, showing that CYB003 dosing led to a rapid and robust psychedelic response in participants at low doses, while maintaining a safe and well-tolerated therapeutic profile.
Upcoming milestones for the CYB003 program:
- Completion of CYB003 dosing in MDD cohorts expected in Q3 2023
- Topline efficacy data readout from CYB003 Phase 2 clinical trial expected in Q3/Q4 2023
- U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2a data for pivotal studies expected following topline efficacy data readout
About the Phase 1/2a CYB003 Trial
The Phase 1/2a trial is a randomized, double-blind, placebo-controlled study evaluating CYB003 in participants with moderate to severe MDD and in healthy volunteers. Per a protocol amendment that was announced on February 28, 2023, the study introduced healthy volunteers for the lower (sub-therapeutic) dose cohorts and added a bioequivalence and food effect cohort to facilitate the transition to pivotal studies. Healthy volunteers receive two administrations (placebo/active and active/active) one week apart, and measures of psychedelic effect are assessed after each dose. Participants with MDD receive two administrations (placebo/active and active/active) three weeks apart and response/remission are assessed three weeks after each dose. MDD participants in the trial that are currently being treated with antidepressants will be allowed to remain on their antidepressant medication.
The study will evaluate the safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics (“PD”), and psychedelic effect of ascending oral doses of CYB003. In participants with MDD, the trial will also assess rapid onset of antidepressant effect on the day of dosing, using the Montgomery-Asberg Depression Rating Scale (“MADRS”) and evaluate the incremental benefit of a second dose of CYB003 when administered at Week 3. An optional period of assessment will help determine the durability of treatment effect out to 12 weeks. The study is listed on ClinicalTrials.gov under Identifier: NCT05385783.
About Cybin
Cybin (or the “Company”) is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.
Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on Twitter, LinkedIn, YouTube and Instagram.
